Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00382109 · OUTCOME

Estimated Percentage of Participants With Event Free Survival

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission · Source last updated 2019-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
at 2 years

What was measured

An event is defined as relapse or transplant-related mortality. Relapse is defined in section 3.3 study protocol.

Analysis population: Two ineligible patients on experimental arm excluded from analysis.

Groups in this outcome

Experimental

Tacro-MTX/Sirolimus GVHD Prophylaxis

Control

Tacro-MTX GVHD Prophylaxis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Experimental74
Control70

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Experimental45Not reported3460Not reported
Control54Not reported4169Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        34
        upper Limit
        60
        value
        45
      2. group Id
        OG001
        lower Limit
        41
        upper Limit
        69
        value
        54
denoms
  1. counts
    1. group Id
      OG000
      value
      74
    2. group Id
      OG001
      value
      70
    units
    Participants
description
An event is defined as relapse or transplant-related mortality. Relapse is defined in section 3.3 study protocol.
dispersion Type
95% Confidence Interval
groups
  1. description
    Tacro-MTX/Sirolimus GVHD Prophylaxis
    id
    OG000
    title
    Experimental
  2. description
    Tacro-MTX GVHD Prophylaxis
    id
    OG001
    title
    Control
param Type
NUMBER
population Description
Two ineligible patients on experimental arm excluded from analysis.
reporting Status
POSTED
time Frame
at 2 years
title
Estimated Percentage of Participants With Event Free Survival
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice